Výsledky vyhledávání

Costs of multidrug-resistant TB treatment in Finland and Estonia affected by the 2019 WHO guidelines

Autor: Manfred Danilovits, Patovirta Rl, Lea Pehme, Aaltonen Hk, Grierson S, Vasankari T, Vauhkonen M, Piret Viiklepp, Feuth T

Publikováno v: The International Journal of Tuberculosis and Lung Disease

BACKGROUND: Multidrug-resistant TB (MDR-TB) is a growing problem in the effort to end the global TB epidemic. In 2019, the WHO adopted a new standardised regiment for MDR-TB, consisting of only oral medications.METHODS: We estimated the impact of the

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::811cf043d76fc76ce4cbca60b54828b0
http://europepmc.org/articles/PMC8259121

Zobrazit plný text záznamu

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Autor: Shankar-Hari, M, Vale, CL, Godolphin, PJ, Fisher, D, Higgins, JPT, Spiga, F, Savovic, J, Tierney, J, Baron, G, Benbenishty, JS, Berry, LR, Broman, N, Cavalcanti, AB, Colman, R, De Buyser, SL, Derde, LPG, Domingo, P, Omar, SF, Fernandez-Cruz, A, Feuth, T, Garcia, F, Garcia-Vicuna, R, Gonzalez-Alvaro, I, Gordon, AC, Haynes, R, Hermine, O, Horby, PW, Horick, NK, Kumar, K, Lambrecht, BN, Landray, MJ, Leal, L, Lederer, DJ, Lorenzi, E, Mariette, X, Merchante, N, Misnan, NA, Mohan, SV, Nivens, MC, Oksi, J, Perez-Molina, JA, Pizov, R, Porcher, R, Postma, S, Rajasuriar, R, Ramanan, AV, Ravaud, P, Reid, PD, Rutgers, A, Sancho-Lopez, A, Seto, TB, Sivapalasingam, S, Soin, AS, Staplin, N, Stone, JH, Strohbehn, GW, Sunden-Cullberg, J, Torre-Cisneros, J, Tsai, LW, van Hoogstraten, H, van Meerten, T, Veiga, VC, Westerweel, PE, Murthy, S, Diaz, JV, Marshall, JC, Sterne, JAC, Pomar V., Benito N., WHO Rapid Evidence Appraisal COVID

Publikováno v: JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname

IMPORTANCE Clinical trials assessing the efficacy of IL-6 antagonists in patients hospitalized for COVID-19 have variously reported benefit, no effect, and harm. OBJECTIVE To estimate the association between administration of IL-6 antagonists compare

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::a2c5c0ab547ccf2be0501d4122d08556
https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=4406

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání